Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 5
1972 5
1973 11
1974 4
1975 3
1976 3
1977 4
1978 3
1979 5
1980 4
1981 5
1982 3
1983 4
1984 11
1985 6
1986 8
1987 4
1988 3
1989 11
1990 14
1991 10
1992 10
1993 9
1994 17
1995 21
1996 15
1997 16
1998 11
1999 26
2000 18
2001 26
2002 24
2003 23
2004 31
2005 48
2006 41
2007 46
2008 47
2009 70
2010 99
2011 119
2012 128
2013 130
2014 142
2015 191
2016 177
2017 195
2018 219
2019 239
2020 334
2021 378
2022 391
2023 368
2024 332
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

3,617 results

Results by year

Filters applied: . Clear all
Page 1
Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation.
Ali N, Zirak B, Rodriguez RS, Pauli ML, Truong HA, Lai K, Ahn R, Corbin K, Lowe MM, Scharschmidt TC, Taravati K, Tan MR, Ricardo-Gonzalez RR, Nosbaum A, Bertolini M, Liao W, Nestle FO, Paus R, Cotsarelis G, Abbas AK, Rosenblum MD. Ali N, et al. Cell. 2017 Jun 1;169(6):1119-1129.e11. doi: 10.1016/j.cell.2017.05.002. Epub 2017 May 25. Cell. 2017. PMID: 28552347 Free PMC article.
Kissing artifact.
Ali N, D'Agostino R. Ali N, et al. Abdom Radiol (NY). 2021 May;46(5):2258-2260. doi: 10.1007/s00261-020-02660-x. Epub 2020 Nov 26. Abdom Radiol (NY). 2021. PMID: 33244715 Review. No abstract available.
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant.
Vincenti F, Bestard O, Brar A, Cruzado JM, Seron D, Gaber AO, Ali N, Tambur AR, Lee H, Abbadessa G, Paul JA, Dudek M, Siegel RJ, Torija A, Semiond D, Lépine L, Ternes N, Montgomery RA, Stegall M. Vincenti F, et al. Among authors: ali n. J Am Soc Nephrol. 2024 Mar 1;35(3):347-360. doi: 10.1681/ASN.0000000000000287. Epub 2023 Dec 26. J Am Soc Nephrol. 2024. PMID: 38147137 Clinical Trial.
Tissue regulatory T cells.
Lui PP, Cho I, Ali N. Lui PP, et al. Among authors: ali n. Immunology. 2020 Sep;161(1):4-17. doi: 10.1111/imm.13208. Epub 2020 Jun 24. Immunology. 2020. PMID: 32463116 Free PMC article. Review.
The Olympia Declaration.
Pitsiladis YP, Abatzis-Papadopoulos M, Ali N, Aggeloudis S, Atkinson C, Constandache B, Ganus Y, Geladas N, Giakoumakis SI, Güner R, Howman D, Lima GHO, Khristenko E, Koskolou M, Klissouras V, Ladikas M, Loland S, McNamee MJ, Pardos BM, Natsis K, Nicholson P, Betancurt JO, Angeloudis K, Pappas E, Peteraitis M, Petróczi A, Papadopoulou T, Pigozzi F, Saugy M, Simon P, Singleton P, Sizikova E, Sottas PE, Tanaka M, Wang G, Yang H. Pitsiladis YP, et al. Among authors: ali n. Curr Sports Med Rep. 2019 Dec;18(12):448-451. doi: 10.1249/JSR.0000000000000660. Curr Sports Med Rep. 2019. PMID: 31834176 No abstract available.
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
Chauhan J, Grandits M, Palhares LCGF, Mele S, Nakamura M, López-Abente J, Crescioli S, Laddach R, Romero-Clavijo P, Cheung A, Stavraka C, Chenoweth AM, Sow HS, Chiaruttini G, Gilbert AE, Dodev T, Koers A, Pellizzari G, Ilieva KM, Man F, Ali N, Hobbs C, Lombardi S, Lionarons DA, Gould HJ, Beavil AJ, Geh JLC, MacKenzie Ross AD, Healy C, Calonje E, Downward J, Nestle FO, Tsoka S, Josephs DH, Blower PJ, Karagiannis P, Lacy KE, Spicer J, Karagiannis SN, Bax HJ. Chauhan J, et al. Among authors: ali n. Nat Commun. 2023 Apr 25;14(1):2192. doi: 10.1038/s41467-023-37811-3. Nat Commun. 2023. PMID: 37185332 Free PMC article.
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Seddon B, et al. Among authors: ali n. Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4. Lancet Oncol. 2017. PMID: 28882536 Free PMC article. Clinical Trial.
3,617 results